title: [Targeted therapies: towards a new toxicology?].
abstract: Targeted therapies (TT) represent since 10 years, an interesting progress in oncology for many cancers in adjuvant, neoadjuvant or palliative situation. The development of this new class of drugs, with an original mechanism of action, their easy administration, mainly per os, and a particular toxicity profile different from "classical" chemotherapy (CT) leads them entering in the therapeutic arsenal of breast, digestive tract, lung and hematologic cancers, in association with CT. Medical oncologists took rapidly the train of TT, managing a new and original skin, digestive, cardiovascular, endocrine and pulmonary toxicity profile, that remains relatively less important than "classical" CT.
authors: Service de carcinologie médicale, hôpital Abderrahman-Mami, rue Abderrahmen-Mami, 2080 Ariana-Tunis, Tunisie.
authors: S
authors: S
authors: Aissi
authors: M
authors: M
authors: Ben Mrad
authors: S
authors: S
authors: Zarraa
authors: A
authors: A
authors: Bounedjar
authors: S
authors: S
authors: Laabidi
authors: H
authors: H
authors: Boussen
mesh_terms: D000970:Antineoplastic Agents / Q000633:toxicity*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents